18176 Realizing the Promise of CAR-T Cell Therapy for Leukemia and Lymphoma: Implications for Long-Term Care in the Era of Stem Cell Transplantation
In this activity, experts in the management of hematologic malignancies discuss the science behind adoptive immunotherapy with chimeric antigen receptor (CAR)-T cell therapy and exciting new developments with this innovative treatment approach for patients with leukemia and B-cell lymphoma, including the latest efficacy and safety data, recent indications for use of different CAR-T cell constructs, and role in the context of HCT. They also provide insight on practical considerations for appropriate integration of CAR-T cell therapies into treatment plans, identifying patients most likely to benefit from these agents, and strategies for managing unique CAR-T cell–related toxicities.
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists and BMT nurse specialists, and other clinicians involved in the care of patients undergoing HCT.
- Discuss the anticancer mechanisms and the latest evidence on efficacy and safety of adoptive immunotherapy with chimeric antigen receptor (CAR) T cells in various lymphoma and leukemia settings
- Identify the clinical role of and patients that might benefit from CAR T cell therapy in conjunction with current treatment paradigms including HCT for leukemia and lymphoma
- Describe strategies for managing the unique safety issues associated with the use of CAR T cell therapy
Stephan A. Grupp, MD, PhD
Novotny Professor of Pediatrics
University of Pennsylvania Perelman School of Medicine
Chief, Cellular Therapy and Transplant Section
Director, Cancer Immunotherapy Frontier Program
CCCR Director of Translational Research
The Children's Hospital of Philadelphia
Krishna Komanduri, MD
Kalish Family Chair in Stem Cell Transplantation
Professor of Medicine, Microbiology & Immunology
Director, Adult Stem Cell Transplant Program
Sylvester Comprehensive Cancer Center
University of Miami
All persons in control of content have no relevant financial relationships to disclose.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.